Edwards Lifesciences Corp. (NYSE:EW) on Thursday gained U.S. Food and Drug Administration clearance for its AUTUS Size-Adjustable Valve, offering a specialized surgical option for pediatric patients needing pulmonary valve replacement due to congenital heart disease.
The newly approved medical device addresses a critical healthcare gap by expanding inside a growing child’s body through a minimally invasive transcatheter procedure, potentially sparing young patients from multiple open-heart surgeries.
Innovative Design Meets Pediatric Needs
The device starts at an initial implant size of roughly 13 millimeters—suitable for toddlers and preschool-aged children—and expands up to 22 millimeters using a balloon catheter. This upper limit matches standard adult pulmonary valve dimensions.
Unlike conventional heart valves that rely on animal tissue susceptible to premature hardening and degradation in pediatric patients, the AUTUS valve incorporates synthetic polymeric leaflets.
The FDA approval marks the first time a valve utilizing polymeric leaflet material has received clearance for any medical application.
One-year follow-up clinical data indicate these synthetic components maintain structural integrity over time.
Strong Clinical Study Results
Regulatory approval is based on comprehensive clinical trial evidence involving 62 pediatric patients.
Trial participants experienced a 100% success rate with zero reported deaths, strokes, or blood clots requiring intervention.
Within 30 days post-procedure, all patients remained free from device-related complications. At six months, participants demonstrated stable blood flow and minimal valve leakage.
One-year assessments confirmed consistent performance, maintaining low pressure gradients across the right ventricular outflow tract, minimal regurgitation, and no required reinterventions.
Expanding Congenital Treatment Options
While three patients experienced valve frame fractures and two displayed reduced leaflet motion, none suffered adverse symptoms.
Physicians expanded valves in two patients who began outgrowing them without requiring invasive surgery. Long-term studies will follow patients for 10 years to gather additional performance data.
The approval strengthens the congenital treatment offerings from Edwards Lifesciences, adding to an existing portfolio that features the SAPIEN 3, the Alterra Adaptive Prestent, and pediatric atrioseptostomy catheters.
EW Stock Price Activity: Edwards Lifesciences shares are trading higher by 1.05% at $86.08 at the time of publication on Friday, according to Benzinga Pro data.
Photo Shutterstock
Login to comment